Sectoral Asset Management INC Trimmed Amicus Therapeutics (FOLD) Position by $16.07 Million as Share Price Rose

February 15, 2018 - By Darrin Black

Investors sentiment increased to 2.33 in Q3 2017. Its up 1.10, from 1.23 in 2017Q2. It improved, as 16 investors sold FOLD shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Cornerstone Capital Management Ltd Co reported 68,532 shares. Geode Capital Management Llc has invested 0.01% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Moreover, Us Bancorporation De has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 813 shares. Pacad Ltd invested 0.11% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Smith Asset Limited Partnership invested in 31,400 shares or 0.02% of the stock. Sg Americas Securities Limited Liability Co stated it has 10,888 shares or 0% of all its holdings. Moreover, Advisory Serv Ntwk Limited Liability Company has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD). 23,431 were reported by Numeric Invsts Limited Liability. 68,568 were reported by First Midwest Retail Bank Trust Division. 6.06 million were reported by Wellington Mgmt Llp. Cubist Systematic Strategies Lc reported 15,300 shares. 219,833 are held by Federated Invsts Pa. Artal Gru accumulated 700,000 shares. Lpl Fincl Ltd reported 15,465 shares. Wells Fargo And Company Mn reported 0% stake.

Since October 12, 2017, it had 0 insider purchases, and 16 selling transactions for $11.04 million activity. $1.06M worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were sold by Crowley John F. On Thursday, October 12 Do Hung sold $715,360 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 50,194 shares. RAAB MICHAEL also sold $140,490 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares. HAYDEN DONALD J JR sold $300,002 worth of stock or 20,000 shares. Shares for $73,559 were sold by Barth Jay. On Tuesday, January 2 Baird William D III sold $147,181 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 10,000 shares.

Jerome Pfund decreased its stake in Amicus Therapeutics (FOLD) by 30.74% based on its latest 2017Q3 regulatory filing with the SEC. Sectoral Asset Management Inc sold 1.07M shares as the company’s stock rose 23.92% with the market. The hedge fund run by Jerome Pfund held 2.41 million shares of the health care company at the end of 2017Q3, valued at $36.39 million, down from 3.48M at the end of the previous reported quarter. Sectoral Asset Management Inc who had been investing in Amicus Therapeutics for a number of months, seems to be less bullish one the $2.69B market cap company. The stock increased 3.22% or $0.505 during the last trading session, reaching $16.185. About 2.97M shares traded or 16.44% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since February 15, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Sectoral Asset Management Inc, which manages about $3.30 billion and $776.31M US Long portfolio, upped its stake in Portola Pharmaceuticals (NASDAQ:PTLA) by 84,271 shares to 506,414 shares, valued at $27.36M in 2017Q3, according to the filing.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on March, 7. They expect $-0.30 EPS, up 6.25 % or $0.02 from last year’s $-0.32 per share. After $-0.41 actual EPS reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -26.83 % EPS growth.

More notable recent Amicus Therapeutics, Inc. (NASDAQ:FOLD) news were published by: which released: “Amicus Therapeutics to Present at LEERINK Partners 7th Annual Global …” on February 13, 2018, also with their article: “Amicus Therapeutics: What To Expect In 2018” published on January 24, 2018, published: “Amicus Therapeutics Launches Galafoldâ„¢ (Migalastat) for Treatment of Fabry …” on January 17, 2018. More interesting news about Amicus Therapeutics, Inc. (NASDAQ:FOLD) were released by: and their article: “Amicus Therapeutics: Pompe Data Strengthens Bullish Thesis” published on February 08, 2018 as well as‘s news article titled: “Amicus Therapeutics: Positive Data For Pompe Disease And Recent Regulatory …” with publication date: February 13, 2018.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. Cowen & Co maintained the shares of FOLD in report on Tuesday, July 11 with “Buy” rating. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, March 30. On Tuesday, January 24 the stock rating was upgraded by Robert W. Baird to “Outperform”. The company was initiated on Thursday, April 14 by Robert W. Baird. On Sunday, August 13 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Sunday, June 25 by Cowen & Co. The stock has “Buy” rating by Bank of America on Wednesday, May 18. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Overweight” rating by JP Morgan on Tuesday, September 8. The firm has “Outperform” rating given on Monday, October 5 by Leerink Swann. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) has “Buy” rating given on Monday, August 7 by Cowen & Co.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.